Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 1c

Syros Reports Fourth Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

March 5, 2020 7:30 AM EST

Initiated Phase 1 Clinical Trial of SY-5609 in Select Solid Tumors Patients

Entered into Collaboration with GBT to Advance Novel Therapies for Sickle Cell Disease and Beta Thalassemia

Well-funded with cash runway into 2022 beyond multiple expected clinical data readouts for SY-1425 and SY-5609

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today reported... More